<DOC>
	<DOCNO>NCT01390844</DOCNO>
	<brief_summary>This study ass efficacy boceprevir ( BOC ) combination PegIntron ( pegylated interferon alfa-2b ) ( PEG ) ribavirin ( RBV ) response guide therapy compare efficacy standard-of-care therapy alone adult subject chronic hepatitis C ( CHC ) genotype 1 fail prior treatment pegylated interferon RBV Asia Pacific population . The primary hypothesis proportion participant achieve sustain virologic response experimental therapy regimen ( BOC/PEG+RBV ) superior control arm ( Placebo/PEG+RBV ) , Full Analysis Set ( FAS ) population .</brief_summary>
	<brief_title>Safety Efficacy Boceprevir Asia Pacific Participants With Chronic Hepatitis C Genotype 1 ( P07063 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Previously document CHC genotype 1 infection . Other mixed genotype eligible . Liver biopsy histology consistent CHC etiology . Participants cirrhosis must ultrasound/imaging study within 6 month screen ( screen Day 1 ) finding suspicious hepatocellular carcinoma Failed previous treatment ( least 12 week ) pegylated interferon ( alfa2a alfa2b ) plus RBV Weight 40 kg 125 kg , inclusive Of 'local ' ancestral descent Sexually active male female childbearing potential must agree use medically accept method contraception Coinfected human immunodeficiency virus ( HIV ) hepatitis B virus . Required discontinuation previous interferon RBV regimen adverse event consider possibly probably related RBV and/or interferon . Treatment RBV within 90 day interferonalpha within 1 month prior screen . Treatment hepatitis C investigational medication prior treatment herbal remedy know hepatotoxicity . Treatment investigational drug participation interventional clinical trial within 30 day screen visit . Evidence decompensated liver disease include , limited , history presence clinical ascites , bleed varix , hepatic encephalopathy . Diabetes and/or hypertension clinically significant ocular examination finding . Any condition could interfere participation completion trial . Evidence active suspect malignancy , history malignancy within last 5 year ( except adequately treatment carcinoma situ basal cell carcinoma skin ) . Pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>